アタザナビル

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H319：強い眼刺激

• 注意書き

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

アタザナビル 価格

アタザナビル 化学特性,用途語,生産方法

• 用途

  アタザナビル(Atazanavir)は商標名のレイアタッツ(Reyataz)として販売されており、抗レトロウィルス薬としてHIV/エイズの治療と予防に用いられる医薬品である。一般的に他の抗レトロウィルス薬との併用が勧められる。

• 効能

  抗ウイルス薬, HIVプロテアーゼ阻害薬

• 化学的特性

  Crystalline Solid

• 使用

  Atazanavir is a novel azapeptide protease inhibitor (PI)

• 定義

  ChEBI: A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).

• 獲得抵抗性

  Mutations at positions 50 (I50L), 84 (I84V) and 88 (N88S) of the protease gene are associated with resistance.

• 一般的な説明

  Atazanavir is an antiretroviral agent that has been approvedby the FDA for use in combination with other anti-RTagents for the treatment of HIV infections. The drug is alwaysused in combination with RT inhibitors.

• 応用例（製薬）

  An azapeptide formulated as the sulfate for oral use.

• 作用機序

  Atazanavir is dosed orally once daily, thus reducing "pill burden," and it appears to have minimal impact on lipid parameters but does increase total bilirubin. The drug is well absorbed when administered orally with food (bioavailability, ~68%). The drug is highly bound to plasma protein (86%) and is metabolized by CYP3A isoenzyme. Atazanavir is a moderate inhibitor of CYP3A, and potential drug–drug interactions are possible with CYP3A inhibitors and inducers.

• 薬物動態学

  Oral absorption: c. 68%
  C_max 400 mg once daily: c. 3.15 μg/L
  300 mg + ritonavir 100 mg once daily: c. 4.47 μg/L
  C_min 400 mg once daily: c. 0.27 μg/L
  300 mg + ritonavir 100 mg once daily: c. 0.65 μg/L
  Plasma half-life: c. 8.6 h (300 mg+ ritonavir 100 mg)
  Volume of distribution: c. Not known/available
  Plasma protein binding: c. 86%
  Absorption
  Administration with food enhances bioavailability and reduces pharmacokinetic variability. Absorption is dependent on gastric pH. It should be given separately from proton-pump inhibitors or H2-receptor antagonists. Buffered or entericcoated formulations should be given (with food) 2 h before or 1 h after co-administration of didanosine.
  Distribution
  It penetrates moderately well into the CNS. The semen:plasma ratio is 0.11–4.42. It is distributed into breast milk.
  Metabolism
  It is extensively metabolized by CYP3A4. Administration with ritonavir prevents metabolization and enhances the pharmacokinetic profile.
  Excretion
  Following a single 400 mg dose, 79% and 13% of the dose was recovered in the feces and urine, respectively. It should be used with caution in the presence of mild hepatic impairment and should not be used in patients with more severe hepatic impairment.

• 臨床応用

  Treatment of HIV infection (in combination with other antiretroviral drugs)

• 副作用

  The most common adverse reactions (≥2%) are nausea, jaundice/ scleral icterus, rash, headache, abdominal pain, vomiting, insomnia, peripheral neurological symptoms, dizziness, myalgia, diarrhea, depression and fever.

アタザナビル 上流と下流の製品情報

アタザナビル 生産企業

Global(324)Suppliers

アタザナビル スペクトルデータ(¹HNMR)

198904-31-3, アタザナビル キーワード